Indian pharma faces a major jolt as President Trump slaps 100% tariffs on branded and patented medicines from October. While the move spares companies setting up plants in the US, it puts at risk nearly $1 billion worth of Indian exports. The US, India’s biggest pharma market, buys a third of its drug exports—dominated by low-cost generics that power America’s affordable healthcare.
Oneweb 2027 Plans: New Tech, New Features
Vinit Bolinjkar's 2026 Market Strategy: Be Selective And Valuation-Driven
Accenture Results Spark Fresh Buzz In IT, Early Turn Or Just A Bounce?
Hate Speech Bill Sparks Chaos In Karnataka Assembly, Opposition Cries Free Speech Attack
High-Profile Names Appear In New Epstein Photo Release Ahead Of Deadline
